Suppr超能文献

通过……调节信号通路促进肝细胞癌中的脂质代谢。

promotes lipid metabolism in hepatocellular carcinoma by regulating the signaling pathway through .

作者信息

Sun Yaocheng, Shen Ying, Yan Yongmin, Luo Wei, Liu Chuanlei, Tang Jianjun

机构信息

Department of General Surgery, The Wujin Clinical College of Xuzhou Medical University Changzhou 213017, Jiangsu, China.

Department of General Surgery, Wujin Hospital Affiliated with Jiangsu University Changzhou 213017, Jiangsu, China.

出版信息

Am J Transl Res. 2025 Apr 15;17(4):2527-2540. doi: 10.62347/ZTGP5030. eCollection 2025.

Abstract

OBJECTIVES

Cancer cells exhibit altered metabolic profiles. Glutaminase 1 (), a key enzyme in cancer cells, promoting glutamine catabolism to glutamate and ammonia, is strongly associated with various human malignancies.

METHODS

promotes lipid accumulation and cell proliferation by upregulating the expression of sterol regulatory element-binding protein 1 () and SREBP cleavage-activating protein (). Mechanistically, promotes lipid metabolism in HCC cells through the activation of the pathway.

RESULTS

's role in lipid metabolism in hepatocellular carcinoma (HCC) remains unexplored. Our findings indicate that is not only significantly overexpressed in HCC but also negatively correlates with clinical prognosis. Further investigation revealed that drives lipid accumulation and de novo fatty acid synthesis in HCC.

CONCLUSIONS

Our study suggests that mediates to drive lipid metabolism in HCC via the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin complex 1 () signaling pathway, thus we present as a potential biomarker and therapeutic target for HCC.

摘要

目的

癌细胞表现出代谢谱的改变。谷氨酰胺酶1()是癌细胞中的一种关键酶,可促进谷氨酰胺分解为谷氨酸和氨,与多种人类恶性肿瘤密切相关。

方法

通过上调固醇调节元件结合蛋白1()和SREBP裂解激活蛋白()的表达促进脂质积累和细胞增殖。机制上,通过激活途径促进肝癌细胞的脂质代谢。

结果

在肝细胞癌(HCC)脂质代谢中的作用仍未被探索。我们的研究结果表明,不仅在肝癌中显著过表达,而且与临床预后呈负相关。进一步研究发现,在肝癌中驱动脂质积累和从头脂肪酸合成。

结论

我们的研究表明,通过磷脂酰肌醇-3-激酶/蛋白激酶B/雷帕霉素复合物1()信号通路介导驱动肝癌中的脂质代谢,因此我们提出作为肝癌的潜在生物标志物和治疗靶点。

相似文献

1
promotes lipid metabolism in hepatocellular carcinoma by regulating the signaling pathway through .
Am J Transl Res. 2025 Apr 15;17(4):2527-2540. doi: 10.62347/ZTGP5030. eCollection 2025.
2
GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway.
Exp Cell Res. 2019 Aug 1;381(1):1-9. doi: 10.1016/j.yexcr.2019.04.005. Epub 2019 May 3.
3
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Acta Pharm Sin B. 2022 Feb;12(2):558-580. doi: 10.1016/j.apsb.2021.09.019. Epub 2021 Sep 25.
5
Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.
J Cell Mol Med. 2017 Nov;21(11):3023-3043. doi: 10.1111/jcmm.13213. Epub 2017 May 30.
6
Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma.
Clin Transl Med. 2022 May;12(5):e852. doi: 10.1002/ctm2.852.
8
Nuclear factor-κB p65 regulates glutaminase 1 expression in human hepatocellular carcinoma.
Onco Targets Ther. 2018 Jun 28;11:3721-3729. doi: 10.2147/OTT.S167408. eCollection 2018.
10
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Gastroenterology. 2011 Mar;140(3):1071-83. doi: 10.1053/j.gastro.2010.12.006. Epub 2010 Dec 11.

本文引用的文献

1
Targeting SREBP-1-Mediated Lipogenesis as Potential Strategies for Cancer.
Front Oncol. 2022 Jul 14;12:952371. doi: 10.3389/fonc.2022.952371. eCollection 2022.
2
Lipid metabolism in tumor microenvironment: novel therapeutic targets.
Cancer Cell Int. 2022 Jul 5;22(1):224. doi: 10.1186/s12935-022-02645-4.
3
ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyroid cancer cells.
Endocrine. 2022 Oct;78(1):85-94. doi: 10.1007/s12020-022-03124-6. Epub 2022 Jun 27.
4
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches.
Pharmaceutics. 2022 Jun 19;14(6):1303. doi: 10.3390/pharmaceutics14061303.
5
Metabolic reprogramming: a bridge between aging and tumorigenesis.
Mol Oncol. 2022 Sep;16(18):3295-3318. doi: 10.1002/1878-0261.13261. Epub 2022 Jun 19.
7
Risk factors for HCC in contemporary cohorts of patients with cirrhosis.
Hepatology. 2023 Mar 1;77(3):997-1005. doi: 10.1002/hep.32434. Epub 2023 Feb 17.
9
SREBP-1c and lipogenesis in the liver: an update1.
Biochem J. 2021 Oct 29;478(20):3723-3739. doi: 10.1042/BCJ20210071.
10
Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer.
Cells. 2021 Jul 6;10(7):1715. doi: 10.3390/cells10071715.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验